{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:27:21Z","timestamp":1794580041878,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003206","name":"Alberta Children\u2019s Hospital Foundation","doi-asserted-by":"publisher","award":["One Child Every Child Postdoctoral Fellowship"],"award-info":[{"award-number":["One Child Every Child Postdoctoral Fellowship"]}],"id":[{"id":"10.13039\/501100003206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002784","name":"Canada Excellence Research Chairs, Government of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001805","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001805","id-type":"DOI","asserted-by":"publisher"}]},{"name":"United Way of Calgary"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Public Health"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.17269\/s41997-026-01179-w","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:16:29Z","timestamp":1775067389000},"page":"1115-1131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-medical opioid (NMO) use in Canadian adolescents: Trends, risk factors, and regional variations"],"prefix":"10.17269","volume":"117","author":[{"given":"Samarpreet","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-6287","authenticated-orcid":false,"given":"David","family":"Borkenhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Mushquash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Dimitropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"1179_CR1","unstructured":"Alberta Health, Alberta Health: Analytics and Performance Reporting Branch, & Government of Alberta. (2017). Opioids and substances of misuse among First Nations People in Alberta. In Alberta Report (pp. 1\u20134) [Report]. https:\/\/open.alberta.ca\/dataset\/cb00bdd1-5d55-485a-9953-724832f373c3\/resource\/31c4f309-26d4-46cf-b8b2-3a990510077c\/download\/opioids-substances-misuse-report-firstnations-2017.pdf. Accessed 24 Sept 2024"},{"issue":"8","key":"1179_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/070674371105600808","volume":"56","author":"E Amari","year":"2011","unstructured":"Amari, E., Rehm, J., Goldner, E., & Fischer, B. (2011). Nonmedical prescription opioid use and mental health and pain comorbidities: A narrative review. Canadian Journal of Psychiatry, 56(8), 495\u2013502. https:\/\/doi.org\/10.1177\/070674371105600808","journal-title":"Canadian Journal of Psychiatry"},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2017.03.011","volume":"92","author":"LP Ashrafioun","year":"2017","unstructured":"Ashrafioun, L. P., Bishop, T. M. P., Conner, K. R. P. M. P. H., & Pigeon, W. R. P. (2017). Frequency of prescription opioid misuse and suicidal ideation, planning, and attempts. Journal of Psychiatric Research, 92, 1\u20137. https:\/\/doi.org\/10.1016\/j.jpsychires.2017.03.011","journal-title":"Journal of Psychiatric Research"},{"key":"1179_CR4","doi-asserted-by":"publisher","unstructured":"Belzak, L., & Halverson, J. (2018). The opioid crisis in Canada: A national perspective. Health Promotion and Chronic Disease Prevention in Canada, 38(6), 224\u2013233. https:\/\/doi.org\/10.24095\/hpcdp.38.6.02. (La crise des opio\u00efdes au Canada\u202f: une perspective nationale.).","DOI":"10.24095\/hpcdp.38.6.02"},{"key":"1179_CR5","unstructured":"Boak, A. H. H., Adlaf, E. M., & Mann, R. E. (2015). Drug use among Ontario students, 1977\u20132015: Detailed OSDUHS findings (CAMH research document series no. 41). Toronto: Centre for Addiction and Mental Health."},{"key":"1179_CR6","first-page":"1","volume-title":"2018\/2019 Canadian student tobacco, alcohol and drugs survey microdata user guide","author":"R Burkhalter","year":"2019","unstructured":"Burkhalter, R., Thompson-Haile, A., & Cooke, M. (2019). 2018\/2019 Canadian student tobacco, alcohol and drugs survey microdata user guide (pp. 1\u201339). Propel Centre for Population Health Impact: University of Waterloo."},{"key":"1179_CR7","first-page":"1","volume-title":"2016\/2017 Canadian student, tobacco, alcohol and drugs survey microdata user guide","author":"R Burkhalter","year":"2017","unstructured":"Burkhalter, R., Thompson-Haile, A., Rynard, V., & Manske, S. (2017). 2016\/2017 Canadian student, tobacco, alcohol and drugs survey microdata user guide (pp. 1\u201351). Propel Centre for PopulationHealth Impact: University of Waterloo."},{"key":"1179_CR8","unstructured":"Canadian Centre on Substance Abuse. (2014). CCENDU drug alert: Increasing availability of counterfeit oxycodone tablets containing fentanyl (CCSA-CCENDU Stamp 2014).\u00a0https:\/\/www.ccsa.ca\/sites\/default\/files\/2019-05\/CCSA-CCENDU-Oxycontin-Fentanyl-Alert-2014-en.pdf. Accessed 14 Nov 2025"},{"key":"1179_CR9","unstructured":"Canadian Centre on Substance Use and Addiction. (2020). Canadian drug summary: Methamphetamine. https:\/\/www.substanceuse.ca\/sites\/default\/files\/2021-03\/CCSA-Canadian-Drug-Summary-Methamphetamine-2020-en.pdf"},{"key":"1179_CR10","unstructured":"Canadian Centre on Substance Use and Addiction. (2022a). Canadian drug summary: Cocaine.\u00a0https:\/\/www.ccsa.ca\/sites\/default\/files\/2022-10\/CCSA-Canadian-Drug-Summary-Cocaine-2022-en.pdf. Accessed 14 Nov 2025"},{"key":"1179_CR11","doi-asserted-by":"crossref","unstructured":"Canadian Centre on Substance Use and Addiction. (2022b). Canadian drug summary: 3,4-Methylenedioxy-methamphetamine (MDMA, ecstasy or molly). https:\/\/www.ccsa.ca\/sites\/default\/files\/2022-10\/CCSA-MDMA-Ecstasy-Drug-Summary-2022-en.pdf.\u00a0Accessed 14 Nov 2025","DOI":"10.2174\/9789815223828124010004"},{"issue":"8","key":"1179_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1526-4637.2006.00200.x","volume":"8","author":"MJ Edlund","year":"2007","unstructured":"Edlund, M. J., Sullivan, M., Steffick, D., Harris, K. M., & Wells, K. B. (2007). Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Medicine, 8(8), 647\u2013656. https:\/\/doi.org\/10.1111\/j.1526-4637.2006.00200.x","journal-title":"Pain Medicine"},{"issue":"5","key":"1179_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/dar.13832","volume":"43","author":"JM Ezell","year":"2024","unstructured":"Ezell, J. M., Pho, M. T., Ajayi, B. P., Simek, E., Shetty, N., Goddard\u2010Eckrich, D. A., & Bluthenthal, R. N. (2024). Opioid use, prescribing and fatal overdose patterns among racial\/ethnic minorities in the United States: A scoping review and conceptual risk environment model. Drug and Alcohol Review, 43(5), 1143\u20131159. https:\/\/doi.org\/10.1111\/dar.13832","journal-title":"Drug and Alcohol Review"},{"issue":"3","key":"1179_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.36076\/ppj.2018.3.219","volume":"21","author":"B Fischer","year":"2018","unstructured":"Fischer, B., Jones, W., Vojtila, L., & Kurdyak, P. (2018a). Patterns, changes, and trends in prescription opioid dispensing in Canada, 2005\u20132016. Pain Physician, 21(3), 219\u2013228.","journal-title":"Pain Physician"},{"issue":"9","key":"1179_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/070674371005500909","volume":"55","author":"B Fischer","year":"2010","unstructured":"Fischer, B., Nakamura, N., Ialomiteanu, A., Boak, A., & Rehm, J. (2010). Assessing the prevalence of nonmedical prescription opioid use in the general Canadian population: Methodological issues and questions. Canadian Journal of Psychiatry, 55(9), 606\u2013609. https:\/\/doi.org\/10.1177\/070674371005500909","journal-title":"Canadian Journal of Psychiatry"},{"key":"1179_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ypmed.2017.11.001","volume":"107","author":"B Fischer","year":"2018","unstructured":"Fischer, B., Vojtila, L., & Rehm, J. (2018b). The \u2018fentanyl epidemic\u2019 in Canada \u2013 Some cautionary observations focusing on opioid-related mortality. Preventive Medicine, 107, 109\u2013113. https:\/\/doi.org\/10.1016\/j.ypmed.2017.11.001","journal-title":"Preventive Medicine"},{"key":"1179_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15474-5","volume":"23","author":"A Foreman-Mackey","year":"2023","unstructured":"Foreman-Mackey, A., Xavier, J., Corser, J., et al. (2023). \u201cIt\u2019s just a perfect storm\u201d: Exploring the consequences of the COVID-19 pandemic on overdose risk in British Columbia from the perspectives of people who use substances. BMC Public Health, 23, Article 640. https:\/\/doi.org\/10.1186\/s12889-023-15474-5","journal-title":"BMC Public Health"},{"issue":"4","key":"1179_CR18","doi-asserted-by":"publisher","first-page":"E800","DOI":"10.9778\/cmajo.20170104","volume":"5","author":"T Gomes","year":"2017","unstructured":"Gomes, T., Mastorakos, A., Paterson, J. M., Sketris, I., Caetano, P., Greaves, S., Henry, D., Suissa, S., Dormuth, C. R., Hemmelgarn, B. R., Teare, G. F., Chateau, D., Henry, D. A., LeLorier, J., Levy, A. R., Ernst, P., Filion, K. B., Platt, R. W., & Sketris, I. S. (2017). Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: A time series analysis. CMAJ Open, 5(4), E800\u2013E807. https:\/\/doi.org\/10.9778\/cmajo.20170104","journal-title":"CMAJ Open"},{"key":"1179_CR19","unstructured":"Government of Canada. (2025). Health Canada Drug Analysis Service. In focus: The emergence of opioids in Canada. Longueuil (QC), 2025. Retrieved from\u00a0https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/healthy-living\/emergence-opioids-canada.html. Accessed 12 Nov 2025"},{"key":"1179_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19095122","author":"C Goyer","year":"2022","unstructured":"Goyer, C., Castillon, G., & Moride, Y. (2022). Implementation of interventions and policies on opioids and awareness of opioid-related harms in Canada: A multistage mixed methods descriptive study. International Journal of Environmental Research and Public Health. https:\/\/doi.org\/10.3390\/ijerph19095122","journal-title":"International Journal of Environmental Research and Public Health"},{"key":"1179_CR21","doi-asserted-by":"publisher","unstructured":"Havens, J. R., Young, A. M., & Havens, C. E. (2010). Nonmedical prescription drug use in a nationally representative sample of adolescents. Archives of Pediatrics and Adolescent Medicine, 165(3). https:\/\/doi.org\/10.1001\/archpediatrics.2010.217","DOI":"10.1001\/archpediatrics.2010.217"},{"key":"1179_CR22","unstructured":"Health Canada. (2025). Canadian Student Alcohol and Drugs Survey (CSADS) 2023\u201324: Public Use Microdata File (PUMF) [Data file]. Government of Canada: Ottawa (ON). Available from:  https:\/\/open.canada.ca\/data\/dataset\/1f15ca45-8bfd-4f9c-9ec6-2c0c440e69c2. Accessed 13 Nov 2025"},{"key":"1179_CR23","unstructured":"Health Canada. (2021). Drug Analysis Service: Summary report of samples analysed 2016. Canada.ca.\u00a0https:\/\/www.canada.ca\/en\/health-canada\/services\/health-concerns\/controlled-substances-precursor-chemicals\/drug-analysis-service\/2016-drug-analysis-service-summary-report-samples-analysed.html. Accessed 12\u00a0Nov 2025"},{"key":"1179_CR24","unstructured":"Health Canada. (2024). Fentanyl. Canada.ca.\u00a0https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-use\/controlled-illegal-drugs\/fentanyl.html. Accessed 24\u00a0Sept 2024"},{"key":"1179_CR25","unstructured":"Health Canada, & Statistics Canada. (2022). Canadian Student Tobacco, Alcohol and Drugs Survey (CSTADS), 2021\u20132022: Public Use Microdata File (PUMF) [Data file]. Open Data Canada."},{"key":"1179_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.drugalcdep.2017.03.024","volume":"177","author":"M Hu","year":"2017","unstructured":"Hu, M., Griesler, P., Wall, M., & Kandel, D. B. (2017). Age-related patterns in nonmedical prescription opioid use and disorder in the US population at ages 12\u201334 from 2002 to 2014*. Drug and Alcohol Dependence, 177, 237\u2013243. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.03.024","journal-title":"Drug and Alcohol Dependence"},{"key":"1179_CR27","unstructured":"IBM Corp (2023) Released 2023. IBM SPSS Statistics for Windows, Version 29.0.2.0 Armonk, NY: IBM Corp"},{"key":"1179_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100240","volume":"12","author":"RA Kleinman","year":"2024","unstructured":"Kleinman, R. A. (2024). Fentanyl, carfentanil and other fentanyl analogues in Canada\u2019s illicit opioid supply: A cross-sectional study. Drug and Alcohol Dependence Reports, 12, Article 100240. https:\/\/doi.org\/10.1016\/j.dadr.2024.100240","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"2-3","key":"1179_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/1465980512351344101","volume":"10","author":"RA Knibbe","year":"2005","unstructured":"Knibbe, R. A., Joosten, J., Derickx, M., Choquet, M., Morin, D., Monshouwer, K., & Vollebergh, W. (2005). Perceived availability of substances, substance use and substance-related problems: A cross national study among French and Dutch adolescents. Journal of Substance Use, 10(2\u20133), 151\u2013163. https:\/\/doi.org\/10.1080\/1465980512351344101","journal-title":"Journal of Substance Use"},{"issue":"6","key":"1179_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11920-022-01338-z","volume":"24","author":"HM Layman","year":"2022","unstructured":"Layman, H. M., Thorisdottir, I. E., Halldorsdottir, T., Sigfusdottir, I. D., Allegrante, J. P., & Kristjansson, A. L. (2022). Substance use among youth during the COVID-19 pandemic: A systematic review. Current Psychiatry Reports, 24(6), 307\u2013324. https:\/\/doi.org\/10.1007\/s11920-022-01338-z","journal-title":"Current Psychiatry Reports"},{"key":"1179_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.childyouth.2019.104408","volume":"104","author":"V Lopez-Carmen","year":"2019","unstructured":"Lopez-Carmen, V., McCalman, J., Benveniste, T., Askew, D., Spurling, G., Langham, E., & Bainbridge, R. (2019). Working together to improve the mental health of indigenous children: A systematic review. Children and Youth Services Review, 104, Article 104408. https:\/\/doi.org\/10.1016\/j.childyouth.2019.104408","journal-title":"Children and Youth Services Review"},{"issue":"10","key":"1179_CR32","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1097\/j.pain.0000000000000624","volume":"157","author":"SE McCabe","year":"2016","unstructured":"McCabe, S. E., Veliz, P., & Schulenberg, J. E. (2016). Adolescent context of exposure to prescription opioids and substance use disorder symptoms at age 35: A national longitudinal study. Pain, 157(10), 2173\u20132178. https:\/\/doi.org\/10.1097\/j.pain.0000000000000624","journal-title":"Pain"},{"issue":"12","key":"1179_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30676","volume":"3","author":"RK McHugh","year":"2020","unstructured":"McHugh, R. K. (2020). The importance of studying sex and gender differences in opioid misuse. JAMA Network Open, 3(12), Article e2030676. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.30676","journal-title":"JAMA Network Open"},{"issue":"4","key":"1179_CR34","first-page":"E605","volume":"18","author":"Y Murphy","year":"2015","unstructured":"Murphy, Y., Goldner, E. M., & Fischer, B. (2015). Prescription opioid use, harms and interventions in Canada: A review update of new developments and findings since 2010. Pain Physician, 18(4), E605-614.","journal-title":"Pain Physician"},{"issue":"3","key":"1179_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamainternmed.2023.7570","volume":"184","author":"HV Nguyen","year":"2024","unstructured":"Nguyen, H. V., Mital, S., Bugden, S., & McGinty, E. E. (2024). British Columbia\u2019s safer opioid supply policy and opioid outcomes. JAMA Internal Medicine, 184(3), 256\u2013264. https:\/\/doi.org\/10.1001\/jamainternmed.2023.7570","journal-title":"JAMA Internal Medicine"},{"key":"1179_CR36","unstructured":"Ontario Association of Chiefs of Police. (2014). Fentanyl abuse prevention \u2013 a shared responsibility: Fentanyl Patch 4 Patch initiative. Author. https:\/\/www.cacp.ca\/_Library\/drug_abuse_committee_activities\/201508281608391484965819_masterpatch4patchrevmar302015.pdf.\u00a0Accessed 12 Nov 2025"},{"key":"1179_CR37","doi-asserted-by":"publisher","unstructured":"Orpana, H. M., Lang, J. J., Baxi, M., Halverson, J., Kozloff, N., Cahill, L., ..., & Morrison, H. (2018). Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study. Health Promotion and Chronic Disease Prevention in Canada\u202f: Research and Policy,38(6), 234\u2013243. https:\/\/doi.org\/10.24095\/hpcdp.38.6.03. (Tendances canadiennes en mati\u00e8re de mortalit\u00e9 li\u00e9e aux opio\u00efdes et d\u2019invalidit\u00e9 d\u00e9coulant d\u2019un trouble de consommation d\u2019opio\u00efdes, \u00e0 la lumi\u00e8re de l\u2019\u00c9tude sur la charge mondiale de morbidit\u00e9 (1990-2014).).","DOI":"10.24095\/hpcdp.38.6.03"},{"issue":"7","key":"1179_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.25318\/82-003-x202400700002-eng","volume":"35","author":"J Park","year":"2024","unstructured":"Park, J. (2024). Mental health among women and girls of diverse backgrounds in Canada before and during the COVID-19 pandemic: An intersectional analysis. Health Reports, 35(7), 14\u201327. https:\/\/doi.org\/10.25318\/82-003-x202400700002-eng","journal-title":"Health Reports"},{"key":"1179_CR39","unstructured":"Privy Council Office. (2025). Canada\u2019s fentanyl czar \u2013 interim report (June 2025). Government of Canada.\u00a0https:\/\/www.canada.ca\/en\/privy-council\/services\/publications\/canada-fentanyl-czar-interim-report-june-2025.html.\u00a0Accessed 14 Nov 2025"},{"key":"1179_CR40","unstructured":"Public Health Agency of Canada. (2025). Key findings: Opioid- and stimulant-related harms in Canada \u2014 Canada.ca.\u00a0https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/.\u00a0Accessed 12 Nov 2025"},{"key":"1179_CR41","unstructured":"Public Safety Canada. (2024). Question period note: Fentanyl production and precursor chemicals. Retrieved from\u00a0https:\/\/search.open.canada.ca\/qpnotes\/record\/ps-sp,PS-2024-QP-1--MPS-001.\u00a0Accessed 12 Nov 2025"},{"key":"1179_CR42","unstructured":"Rynard, V., Cumming, T., Burkhalter, R., & Manske, S. (2015). 2014\/2015 Canadian student, tobacco, alcohol and drugs survey microdata user guide (pp. 1\u201347). University of Waterloo.\u00a0Accessed 24 Jul 2025"},{"key":"1179_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244x-13-6","volume":"13","author":"KD Shield","year":"2013","unstructured":"Shield, K. D., Ialomiteanu, A., Fischer, B., & Rehm, J. (2013). Assessing the prevalence of non-medical prescription opioid use in the Canadian general adult population: Evidence of large variation depending on survey questions used. BMC Psychiatry, 13, Article 6. https:\/\/doi.org\/10.1186\/1471-244x-13-6","journal-title":"BMC Psychiatry"},{"issue":"6","key":"1179_CR44","doi-asserted-by":"publisher","first-page":"826","DOI":"10.17269\/s41997-020-00450-y","volume":"111","author":"J Smylie","year":"2020","unstructured":"Smylie, J., Marsden, N., Star, L., Gahagan, J., Zarowsky, C., Mykhalovskiy, E., Masuda, J., & Potvin, L. (2020). Requirement for meaningful engagement of First Nations, Inuit, M\u00e9tis, and Indigenous Peoples in publications about them. Exigence de participation concr\u00e8te des Premi\u00e8res nations, des Inuits, des M\u00e9tis et des peuples autochtones aux publications \u00e0 leur sujet. Canadian Journal of Public Health = Revue Canadienne De Sante Publique, 111(6), 826\u2013830. https:\/\/doi.org\/10.17269\/s41997-020-00450-y","journal-title":"Canadian Journal of Public Health = Revue Canadienne De Sante Publique"},{"issue":"2","key":"1179_CR45","first-page":"36","volume":"9","author":"P Tompkins","year":"2018","unstructured":"Tompkins, P. (2018). Confronting the disparity in nonmedical prescription opioid use among rural and urban youth: A call for broader recognition in the era of clandestine fentanyl. UBC Medical Journal, 9(2), 36\u201337.","journal-title":"UBC Medical Journal"},{"key":"1179_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102880","volume":"83","author":"M Tyndall","year":"2020","unstructured":"Tyndall, M. (2020). Safer opioid distribution in response to the COVID-19 pandemic. International Journal of Drug Policy, 83, Article 102880. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102880","journal-title":"International Journal of Drug Policy"},{"key":"1179_CR47","doi-asserted-by":"publisher","unstructured":"Werb, D., Scheim, A. I., Soipe, A., Aeby, S., Rammohan, I., Fischer, B., ..., Marshall, B. D. L. (2022). Health harms of non-medical prescription opioid use: A systematic review. Drug and Alcohol Review, 41(4), 941\u2013952. https:\/\/doi.org\/10.1111\/dar.13441","DOI":"10.1111\/dar.13441"},{"key":"1179_CR48","doi-asserted-by":"publisher","first-page":"173022","DOI":"10.1016\/j.pbb.2020.173022","volume":"198","author":"K Windisch","year":"2020","unstructured":"Windisch, K., & Kreek, M. (2020). Review of addiction risk potential associated with adolescent opioid use. Pharmacology, Biochemistry and Behavior, 198, 173022. https:\/\/doi.org\/10.1016\/j.pbb.2020.173022","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"12","key":"1179_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295145","volume":"18","author":"S Young","year":"2023","unstructured":"Young, S., Gomes, T., Kolla, G., McCormack, D., Dodd, Z., Raboud, J., & Bayoumi, A. M. (2023). Initiations of safer supply hydromorphone increased during the COVID-19 pandemic in Ontario: An interrupted time series analysis. PLoS ONE, 18(12), Article e0295145. https:\/\/doi.org\/10.1371\/journal.pone.0295145","journal-title":"PLoS ONE"},{"issue":"3","key":"1179_CR50","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00213-003-1540-9","volume":"170","author":"JP Zacny","year":"2003","unstructured":"Zacny, J. P., & Gutierrez, S. (2003). Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology (Berl), 170(3), 242\u2013254. https:\/\/doi.org\/10.1007\/s00213-003-1540-9","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"1179_CR51","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/14659891.2020.1736669","volume":"25","author":"AME Zuckermann","year":"2020","unstructured":"Zuckermann, A. M. E., Qian, W., Battista, K., Jiang, Y., de Groh, M., & Leatherdale, S. T. (2020). Factors influencing the non-medical use of prescription opioids among youth: Results from the COMPASS study. Journal of Substance Use, 25(5), 507\u2013514. https:\/\/doi.org\/10.1080\/14659891.2020.1736669","journal-title":"Journal of Substance Use"}],"container-title":["Canadian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-026-01179-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.17269\/s41997-026-01179-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-026-01179-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:57:43Z","timestamp":1794578263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.17269\/s41997-026-01179-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.17269\/s41997-026-01179-w","relation":{},"ISSN":["0008-4263","1920-7476"],"issn-type":[{"value":"0008-4263","type":"print"},{"value":"1920-7476","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study involved a secondary analysis of de-identified data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study involved secondary analysis of de-identified data.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study involved secondary analysis of de-identified data.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Health Canada has not reviewed, approved, nor endorsed this research. Any views expressed or conclusions drawn herein do not necessarily represent those of Health Canada.","order":5,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}]}}